These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39353258)

  • 1. The multiple-action allosteric inhibition of TYK2 by deucravacitinib: Insights from computational simulations.
    Bao Y; Xu R; Guo J
    Comput Biol Chem; 2024 Sep; 113():108224. PubMed ID: 39353258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
    Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
    Front Immunol; 2022; 13():884399. PubMed ID: 35693820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors.
    Wang J; Batista VS; Bunick CG
    bioRxiv; 2023 Oct; ():. PubMed ID: 37873392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.
    Rusiñol L; Puig L
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
    Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
    J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
    Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling.
    Raivola J; Haikarainen T; Silvennoinen O
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31892268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress on the Pharmacological Targeting of Janus Pseudokinases.
    Henry SP; Jorgensen WL
    J Med Chem; 2023 Aug; 66(16):10959-10990. PubMed ID: 37578217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
    Chang Y; Xu S; Ding K
    J Med Chem; 2019 Oct; 62(20):8951-8952. PubMed ID: 31603320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
    Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
    Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of TYK2 pseudokinase domain stabilizers that allosterically inhibit TYK2 signaling.
    Locke GA; Muckelbauer J; Tokarski JS; Barbieri CM; Belić S; Falk B; Tredup J; Wang YK
    Methods Enzymol; 2022; 667():685-727. PubMed ID: 35525559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of imidazo[1,2-
    Moslin R; Gardner D; Santella J; Zhang Y; Duncia JV; Liu C; Lin J; Tokarski JS; Strnad J; Pedicord D; Chen J; Blat Y; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Sack JS; Muckelbauer JK; Chang C; Tredup J; Xie D; Aranibar N; Burke JR; Carter PH; Weinstein DS
    Medchemcomm; 2017 Apr; 8(4):700-712. PubMed ID: 30108788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
    Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
    J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis.
    Kircik L; Aldredge LM; DiRuggiero D
    J Drugs Dermatol; 2024 Aug; 23(8):645-652. PubMed ID: 39093663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.
    Saharinen P; Vihinen M; Silvennoinen O
    Mol Biol Cell; 2003 Apr; 14(4):1448-59. PubMed ID: 12686600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
    Krueger JG; McInnes IB; Blauvelt A
    J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
    Wan X; Ma Y; McClendon CL; Huang LJ; Huang N
    PLoS Comput Biol; 2013 Apr; 9(4):e1003022. PubMed ID: 23592968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain.
    Virtanen AT; Haikarainen T; Sampathkumar P; Palmroth M; Liukkonen S; Liu J; Nekhotiaeva N; Hubbard SR; Silvennoinen O
    Pharmaceuticals (Basel); 2023 Jan; 16(1):. PubMed ID: 36678572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
    Jensen LT; Attfield KE; Feldmann M; Fugger L
    EBioMedicine; 2023 Nov; 97():104840. PubMed ID: 37863021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.